Melbourn promotes Derek Solomon

Moves from laboratory manager to operations director

Melbourn Scientific, a UK provider of analytical and formulation contract research services for the pharma and biotech industries, is broadening its management team with the promotion of laboratory manager Derek Solomon to the new role of operations director.

Solomon joined Melbourn Scientific in 2005 and has overseen the expansion of the services portfolio, which included the recent addition of clinical manufacture to its formulation development services.

You may also like

Research & Development

Intertek acquires Melbourn Scientific

Combines advanced capabilities for measuring device/drug interaction with OINDP drug characterisation expertise
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A finite resource: helium

Although helium may be the second most abundant element in the universe, here on earth this noble gas is rare and precious. In the pharmaceutical industry helium is used for cryogenic cooling of magnets used for MRI and in gas chromatography
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Manufacturing

Naobios and Sumagen sign exclusive partnership to develop HIV vaccine

Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Research & Development

Serum Institute of India collaborates with Univercells to enhance availability of affordable personalised oncology

The partnership endeavours to speed up development times and distribute personalised cancer vaccines to all locations globally, rather than just economically developed countries
Research & Development

Exeliom Biosciences announces three Phase II immuno-oncology clinical trials

Phase II clinical trials will investigate efficacy of lead candidate EXL01 – in gastric cancer with GERCOR, in NSCLC with CHU Lille and in hepatocellular carcinoma with Centre Eugène Marquis of Rennes
Subscribe now